Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 1,392 call options on the company. This is an increase of approximately 633% compared to the typical daily volume of 190 call options.
In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 17,117 shares of the company’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $9.33, for a total transaction of $159,701.61. Following the transaction, the chief financial officer now directly owns 31,585 shares in the company, valued at approximately $294,688.05. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Alan A. Musso sold 6,206 shares of the company’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.89, for a total transaction of $61,377.34. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,165,145 shares of company stock worth $9,696,662. Insiders own 18.77% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Voya Investment Management LLC acquired a new stake in shares of Bellicum Pharmaceuticals in the 2nd quarter valued at approximately $132,000. Commonwealth Equity Services Inc acquired a new stake in shares of Bellicum Pharmaceuticals in the 3rd quarter valued at approximately $142,000. MYDA Advisors LLC acquired a new stake in shares of Bellicum Pharmaceuticals in the 4th quarter valued at approximately $118,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Bellicum Pharmaceuticals in the 3rd quarter valued at approximately $164,000. Finally, Nationwide Fund Advisors raised its position in shares of Bellicum Pharmaceuticals by 30.4% in the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares during the period. Institutional investors and hedge funds own 55.21% of the company’s stock.
Shares of Bellicum Pharmaceuticals (BLCM) opened at $6.60 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08. Bellicum Pharmaceuticals has a 52-week low of $5.02 and a 52-week high of $15.55.
A number of research firms have issued reports on BLCM. ValuEngine downgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Citigroup upped their target price on shares of Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the company a “hold” rating in a research report on Friday. Zacks Investment Research downgraded shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Cantor Fitzgerald restated an “overweight” rating and set a $10.00 target price (down from $12.00) on shares of Bellicum Pharmaceuticals in a research report on Wednesday, January 31st. Finally, Wells Fargo & Co downgraded shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 target price on the stock. in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $16.88.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/18/bellicum-pharmaceuticals-target-of-unusually-high-options-trading-blcm.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.